Sandbox:Preeti: Difference between revisions
Jump to navigation
Jump to search
Preeti Singh (talk | contribs) No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
! | !Category | ||
! | !Disease | ||
! rowspan="3" |Etiology | |||
! | ! colspan="2" rowspan="2" |Mechanism | ||
! colspan=" | ! colspan="12" |Clinical manifestations | ||
! colspan="10" |Laboratory Findings | |||
|- | |- | ||
! | |||
! | |||
! rowspan="2" |Demography | |||
! rowspan="2" |History | |||
! colspan="4" |Symptoms | |||
! colspan="6" |Signs | |||
! colspan="3" |CBC | |||
! rowspan="2" |PBS | |||
! rowspan="2" |LFT | |||
! | |||
! | |||
!Immunochemistry | !Immunochemistry | ||
!Blood work | !Blood work | ||
!Biospy | !Biospy | ||
|- | |||
! | |||
! | |||
!Inherited | |||
!Acquired | |||
!Constitutional b symptoms | |||
!Rash | |||
!Abdominal pain | |||
!Diarrhea | |||
!V/S | |||
!Mass | |||
!LAP | |||
!'''Hepatosplenomegaly''' | |||
!Arthritis | |||
!Other | |||
!WBC | |||
!Hb | |||
!Plt | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |- | ||
| | | | ||
|[[Diffuse large B-cell lymphoma]]] | |[[Diffuse large B-cell lymphoma]]] | ||
|Classified into 2 subtypes based on [[gene expression]] profiles: | |Classified into 2 subtypes based on [[gene expression]] profiles: | ||
*Germinal centre B-cell-like (GCB) | *Germinal centre B-cell-like (GCB) | ||
Line 24: | Line 59: | ||
**Cell-cell interactions in immune niches | **Cell-cell interactions in immune niches | ||
**Production and class-switching of immunoglobulins | **Production and class-switching of immunoglobulins | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* Mass/Lump | * Mass/Lump | ||
Line 36: | Line 75: | ||
: | : | ||
* | * | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* Non tender mass | * Non tender mass | ||
* | * | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* [[Immunohistochemistry]](IHC) | * [[Immunohistochemistry]](IHC) | ||
Line 73: | Line 127: | ||
| | | | ||
* Reciprocal translocation t(14;18)(q32;q21). | * Reciprocal translocation t(14;18)(q32;q21). | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
*[[Fever]] | *[[Fever]] | ||
Line 84: | Line 142: | ||
*[[Dyspnea]] | *[[Dyspnea]] | ||
*Painless swelling in the neck, axilla, groin, thorax and abdomen | *Painless swelling in the neck, axilla, groin, thorax and abdomen | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* [[Lymphadenopathy|Central and peripheral lymphadenopathy]] | * [[Lymphadenopathy|Central and peripheral lymphadenopathy]] | ||
Line 91: | Line 153: | ||
* [[Seizures]] | * [[Seizures]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 102: | Line 175: | ||
** The kappa light chain locus on chromosome 2: t(2;8) | ** The kappa light chain locus on chromosome 2: t(2;8) | ||
** The lambda light chain locus on chromosome 22: t(8;22) | ** The lambda light chain locus on chromosome 22: t(8;22) | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* [[Fever]] | * [[Fever]] | ||
Line 107: | Line 184: | ||
* Unexplained [[weight loss]] | * Unexplained [[weight loss]] | ||
* [[Swollen lymph nodes]] in the neck, axilla, or groin | * [[Swollen lymph nodes]] in the neck, axilla, or groin | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* [[Proptosis]] | * [[Proptosis]] | ||
Line 115: | Line 196: | ||
* [[Lymphadenopathy|Peripheral lymphadenopathy]] | * [[Lymphadenopathy|Peripheral lymphadenopathy]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* [[CD19]] | * [[CD19]] | ||
Line 140: | Line 232: | ||
* [[Chromosomal translocation]] at '''t(11:14)''' | * [[Chromosomal translocation]] at '''t(11:14)''' | ||
** Over-express [[cyclin D1]] | ** Over-express [[cyclin D1]] | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* Stage IV disease | * Stage IV disease | ||
Line 149: | Line 245: | ||
* Weight Loss | * Weight Loss | ||
* Extranodal involvement of gastrointtestinal (GI) tract, lungs, and central nervous system (CNS) | * Extranodal involvement of gastrointtestinal (GI) tract, lungs, and central nervous system (CNS) | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* Generalized lymphadenopathy | * Generalized lymphadenopathy | ||
Line 155: | Line 255: | ||
* Less commonly | * Less commonly | ||
** Palpable masses in skin, breast, and salivary glands | ** Palpable masses in skin, breast, and salivary glands | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* CD5<sup>+</sup> | * CD5<sup>+</sup> | ||
Line 178: | Line 289: | ||
** Extranodal marginal zone lymphoma. | ** Extranodal marginal zone lymphoma. | ||
* Stimulation of antigen receptor by autoantigen and co-stimulatory molecule CD40. | * Stimulation of antigen receptor by autoantigen and co-stimulatory molecule CD40. | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* Depends largely on its location | * Depends largely on its location | ||
Line 188: | Line 303: | ||
** Hashimoto thyroiditis | ** Hashimoto thyroiditis | ||
** Sjögren syndrome. | ** Sjögren syndrome. | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 202: | Line 332: | ||
** Deletion 7q21-32 | ** Deletion 7q21-32 | ||
** Translocations of the CDK6 gene located at 7q21. | ** Translocations of the CDK6 gene located at 7q21. | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 227: | Line 376: | ||
** The ''MEK-ERK'' cascade | ** The ''MEK-ERK'' cascade | ||
** The ''Phosphatidylinositol 3 kinase (PI3K)-AKT'' cascade | ** The ''Phosphatidylinositol 3 kinase (PI3K)-AKT'' cascade | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* [[Fever]] | * [[Fever]] | ||
Line 236: | Line 389: | ||
* Recurrent [[Infection|infections]] | * Recurrent [[Infection|infections]] | ||
* Early satiety | * Early satiety | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* [[Pallor]], | * [[Pallor]], | ||
* [[Petechiae]] | * [[Petechiae]] | ||
* [[Splenomegaly]] | * [[Splenomegaly]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* [[Annexin A1]] | * [[Annexin A1]] | ||
Line 262: | Line 430: | ||
|- | |- | ||
|[[Multiple myeloma|Plasma cell myeloma]] | |[[Multiple myeloma|Plasma cell myeloma]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 270: | Line 457: | ||
|- | |- | ||
|[[Chronic lymphocytic leukemia]] / [[Chronic lymphocytic leukemia|small lymphocytic lymphoma]] | |[[Chronic lymphocytic leukemia]] / [[Chronic lymphocytic leukemia|small lymphocytic lymphoma]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 278: | Line 484: | ||
|- | |- | ||
|[[Monoclonal B-cell lymphocytosis]] | |[[Monoclonal B-cell lymphocytosis]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 286: | Line 511: | ||
|- | |- | ||
|[[B-cell prolymphocytic leukemia]] | |[[B-cell prolymphocytic leukemia]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 294: | Line 538: | ||
|- | |- | ||
|[[Waldenström's macroglobulinemia|Waldenström's macroglubulinemia]] | |[[Waldenström's macroglobulinemia|Waldenström's macroglubulinemia]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 302: | Line 565: | ||
|- | |- | ||
|[[Monoclonal gammopathy of undetermined significance]] (MGUS) | |[[Monoclonal gammopathy of undetermined significance]] (MGUS) | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 310: | Line 592: | ||
|- | |- | ||
|[[Heavy chain disease]] | |[[Heavy chain disease]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 318: | Line 619: | ||
|- | |- | ||
|Solitary plasmacytoma of bone | |Solitary plasmacytoma of bone | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 326: | Line 646: | ||
|- | |- | ||
|Extraosseous plasmacytoma | |Extraosseous plasmacytoma | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 334: | Line 673: | ||
|- | |- | ||
|Monoclonal immunoglobulin deposition diseases | |Monoclonal immunoglobulin deposition diseases | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 342: | Line 700: | ||
|- | |- | ||
|Extranodal marginal zone lymphoma of [[MALT lymphoma|mucosa-associated lymphoid tissue]] (MALT lymphoma) | |Extranodal marginal zone lymphoma of [[MALT lymphoma|mucosa-associated lymphoid tissue]] (MALT lymphoma) | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 350: | Line 727: | ||
|- | |- | ||
|Large B-cell lymphoma with IRF4 rearrangement | |Large B-cell lymphoma with IRF4 rearrangement | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 358: | Line 754: | ||
|- | |- | ||
|[[Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle center lymphoma]] | |[[Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle center lymphoma]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 366: | Line 781: | ||
|- | |- | ||
|T-cell/histiocyte-rich large B-cell lymphoma | |T-cell/histiocyte-rich large B-cell lymphoma | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 374: | Line 808: | ||
|- | |- | ||
|[[Lymphomatoid granulomatosis]] | |[[Lymphomatoid granulomatosis]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 382: | Line 835: | ||
|- | |- | ||
|[[Primary mediastinal large B-cell lymphoma|Primary mediastinal (thymic) large B-cell lymphoma]] | |[[Primary mediastinal large B-cell lymphoma|Primary mediastinal (thymic) large B-cell lymphoma]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 390: | Line 862: | ||
|- | |- | ||
|[[Intravascular large B-cell lymphoma]] | |[[Intravascular large B-cell lymphoma]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 398: | Line 889: | ||
|- | |- | ||
|ALK1 large B-cell lymphoma | |ALK1 large B-cell lymphoma | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 406: | Line 916: | ||
|- | |- | ||
|Plasmablastic lymphoma | |Plasmablastic lymphoma | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 414: | Line 943: | ||
|- | |- | ||
|[[Primary effusion lymphoma]] | |[[Primary effusion lymphoma]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 422: | Line 970: | ||
|- | |- | ||
|High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements | |High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 434: | Line 1,001: | ||
* The [[tumor]] [[Cell (biology)|cells]] originate from [[memory T cells]] or [[skin]] homing [[CD4+ T cells]] expressing [[cutaneous]] [[lymphocyte]] [[antigen]] (CLA) and [[chemokine]] [[receptors]] [[CCR4]]<nowiki/>and CCR7. | * The [[tumor]] [[Cell (biology)|cells]] originate from [[memory T cells]] or [[skin]] homing [[CD4+ T cells]] expressing [[cutaneous]] [[lymphocyte]] [[antigen]] (CLA) and [[chemokine]] [[receptors]] [[CCR4]]<nowiki/>and CCR7. | ||
* It is understood that cutaneous t cell lymphoma (maycosis fungoides, Sezary sydrome ) is the result of malignant T cell that derived from a mature CD41 CD45RO1 memory T cells. | * It is understood that cutaneous t cell lymphoma (maycosis fungoides, Sezary sydrome ) is the result of malignant T cell that derived from a mature CD41 CD45RO1 memory T cells. | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* [[Epidermis (skin)|Epidermal]] [[atrophy]] or poikiloderma | * [[Epidermis (skin)|Epidermal]] [[atrophy]] or poikiloderma | ||
Line 446: | Line 1,017: | ||
* [[Anemia]] | * [[Anemia]] | ||
* May progress to [[Sezary syndrome]] (Skin involvement plus hematogenous dissemination) | * May progress to [[Sezary syndrome]] (Skin involvement plus hematogenous dissemination) | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* Cutaneous manifestaions | * Cutaneous manifestaions | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 460: | Line 1,065: | ||
| | | | ||
|- | |- | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 468: | Line 1,092: | ||
| | | | ||
|- | |- | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 482: | Line 1,125: | ||
** Phosphatidylinositol-3 kinase (PI3K), | ** Phosphatidylinositol-3 kinase (PI3K), | ||
** Mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK) | ** Mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK) | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
Symptoms of T-cell large granular lymphocyte leukemia may include the following: | Symptoms of T-cell large granular lymphocyte leukemia may include the following: | ||
Line 491: | Line 1,138: | ||
* [[Bone pain]] | * [[Bone pain]] | ||
* [[Dyspnea]] | * [[Dyspnea]] | ||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* Usually appear pale and malnourished. | * Usually appear pale and malnourished. | ||
Line 497: | Line 1,148: | ||
* [[Hepatomegaly]] | * [[Hepatomegaly]] | ||
* [[Splenomegaly]] | * [[Splenomegaly]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* [[CD3]]+ | * [[CD3]]+ | ||
Line 513: | Line 1,175: | ||
|- | |- | ||
|[[Subcutaneous panniculitis-like T-cell lymphoma]] | |[[Subcutaneous panniculitis-like T-cell lymphoma]] | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
Line 520: | Line 1,201: | ||
| | | | ||
|} | |} | ||
<references /> |
Revision as of 18:57, 28 December 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]
Category | Disease | Etiology | Mechanism | Clinical manifestations | Laboratory Findings | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | History | Symptoms | Signs | CBC | PBS | LFT | Immunochemistry | Blood work | Biospy | |||||||||||||||||
Inherited | Acquired | Constitutional b symptoms | Rash | Abdominal pain | Diarrhea | V/S | Mass | LAP | Hepatosplenomegaly | Arthritis | Other | WBC | Hb | Plt | ||||||||||||
Diffuse large B-cell lymphoma] | Classified into 2 subtypes based on gene expression profiles:
|
|
|
|
|
Centroblastic
Immunoblastic::
Anaplastic:
| ||||||||||||||||||||
Follicular lymphoma |
|
|
||||||||||||||||||||||||
Burkitt lymphoma |
|
|
|
| ||||||||||||||||||||||
B cell lymphoma | Mantle cell lymphoma |
|
|
|
|
CBC
|
| |||||||||||||||||||
Nodal marginal zone B-cell lymphoma |
|
|
|
| ||||||||||||||||||||||
Splenic marginal zone lymphoma |
|
| ||||||||||||||||||||||||
Hairy cell leukemia |
|
|
| |||||||||||||||||||||||
Plasma cell myeloma | ||||||||||||||||||||||||||
Chronic lymphocytic leukemia / small lymphocytic lymphoma | ||||||||||||||||||||||||||
Monoclonal B-cell lymphocytosis | ||||||||||||||||||||||||||
B-cell prolymphocytic leukemia | ||||||||||||||||||||||||||
Waldenström's macroglubulinemia | ||||||||||||||||||||||||||
Monoclonal gammopathy of undetermined significance (MGUS) | ||||||||||||||||||||||||||
Heavy chain disease | ||||||||||||||||||||||||||
Solitary plasmacytoma of bone | ||||||||||||||||||||||||||
Extraosseous plasmacytoma | ||||||||||||||||||||||||||
Monoclonal immunoglobulin deposition diseases | ||||||||||||||||||||||||||
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) | ||||||||||||||||||||||||||
Large B-cell lymphoma with IRF4 rearrangement | ||||||||||||||||||||||||||
Primary cutaneous follicle center lymphoma | ||||||||||||||||||||||||||
T-cell/histiocyte-rich large B-cell lymphoma | ||||||||||||||||||||||||||
Lymphomatoid granulomatosis | ||||||||||||||||||||||||||
Primary mediastinal (thymic) large B-cell lymphoma | ||||||||||||||||||||||||||
Intravascular large B-cell lymphoma | ||||||||||||||||||||||||||
ALK1 large B-cell lymphoma | ||||||||||||||||||||||||||
Plasmablastic lymphoma | ||||||||||||||||||||||||||
Primary effusion lymphoma | ||||||||||||||||||||||||||
High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements | ||||||||||||||||||||||||||
T cell lymphoma | Mycosis fungoides / Sézary syndrome |
|
|
|
||||||||||||||||||||||
T-cell granular lymphocytic leukemia |
|
Symptoms of T-cell large granular lymphocyte leukemia may include the following: |
|
|
| |||||||||||||||||||||
Subcutaneous panniculitis-like T-cell lymphoma |